In a previous interview, Lee hinted that a period of market volatility is expected, as 2024 heads for a soft landing.

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

In the latest market close, Pfizer (PFE) reached $29.08, with a -0.27% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.77%. Meanwhile, the Dow ...

In a press release, Town Manager Scott Crabtree and Director of Public Health John Fralick reported the town is hosting a COVID-19 and flu vaccine clinic on Oct 23. The clinic will go from 11:30 a.m.

A Pfizer Covid booster vaccination gave a fit 54-year-old chronic pain, NHS doctors found. Larry Lowe, from Omagh in Northern ...

An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...

We recently compiled a list of the David Einhorn’s Stock Portfolio: Top 10 Stocks to Buy. In this article, we are going to ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...